Cancer Research Institute Launches Transformative AI-Driven Immuno-Oncology Initiative Powered by 10x Genomics Technology

Rhea-AI Summary

10x Genomics (NASDAQ: TXG) and the Cancer Research Institute launched a multi-phase, AI-driven immuno-oncology initiative to generate high-resolution single cell and spatial data from more than 20,000 samples to map immune responses to cancer.

The project begins with a pilot to produce ~3,000 samples using 10x Chromium and Xenium to benchmark early AI models, then expands to profile over 500 million cells using Chromium Flex across a broader lab network to inform immunotherapy and vaccine discovery.

Positive

• Scale: Project will generate data from >20,000 samples
• Pilot: Approximately 3,000 samples to benchmark AI models
• Cell profiling: Plan to profile >500 million cells using Chromium Flex

Negative

• None.

News Market Reaction

-3.23%

34 alerts

-3.23% News Effect

-4.3% Trough in 25 min

-$82M Valuation Impact

$2.45B Market Cap

0.6x Rel. Volume

On the day this news was published, TXG declined 3.23%, reflecting a moderate negative market reaction. Argus tracked a trough of -4.3% from its starting point during tracking. Our momentum scanner triggered 34 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $82M from the company's valuation, bringing the market cap to $2.45B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Total samples planned: over 20,000 samples Pilot phase samples: approximately 3,000 samples Cells profiled: more than 500 million cells

3 metrics

Total samples planned over 20,000 samples Multi-phase CRI–10x immuno-oncology initiative

Pilot phase samples approximately 3,000 samples Pilot phase across leading immuno-oncology labs

Cells profiled more than 500 million cells Full project using Chromium Flex single cell assay

Market Reality Check

Price: $20.52 Vol: Volume 3,870,770 is 1.73x...

high vol

$20.52 Last Close

Volume Volume 3,870,770 is 1.73x the 20-day average of 2,231,508, indicating elevated trading interest pre-news. high

Technical Shares at $20.46 were trading above the 200-day MA of $12.59, reflecting a pre-existing uptrend into this AI collaboration.

Peers on Argus

TXG gained 6.07% while key peers showed mixed, mostly modest moves (e.g., OMCL +...

TXG gained 6.07% while key peers showed mixed, mostly modest moves (e.g., OMCL +1.06%, GDRX +0.72%, CERT -4.31%, SDGR -2.34%). This points to a stock-specific reaction rather than a sector-wide AI move.

Historical Context

5 past events · Latest: Dec 29 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 29	Conference appearance	Neutral	+0.9%	Announcement of participation in the J.P. Morgan Healthcare Conference.
Nov 18	Consortium launch	Positive	-0.9%	ASTRA consortium using Xenium to build a pan-cancer spatial atlas.
Nov 11	Conference appearance	Neutral	+0.6%	Announcement of participation in the Wolfe Research Healthcare Conference.
Nov 06	Quarterly earnings	Neutral	-3.6%	Q3 2025 results with $149M revenue and narrowed operating loss.
Oct 29	Product launch	Positive	-3.3%	Launch of next-gen Chromium Flex to scale high-throughput single cell studies.

Pattern Detected

Product and collaboration news, including platform scale-ups and consortia, previously saw mixed price reactions, with some divergence where seemingly positive innovation headlines coincided with next-day declines.

Recent Company History

Over the last few months, 10x Genomics has highlighted a series of strategic and innovation-focused milestones. On Oct 29, 2025, it launched the next generation of Chromium Flex to scale single cell research. Q3 2025 results on Nov 6, 2025 showed $149.0M revenue and a narrowed net loss. Subsequent conference appearances and the ASTRA pan-cancer spatial atlas collaboration underscored its role in large-scale cancer and spatial biology projects. Today’s AI-driven CRI initiative extends this trajectory toward massive, multi-institutional datasets.

Market Pulse Summary

This announcement details a multi-phase CRI–10x collaboration to create AI-ready immuno-oncology dat...

Analysis

This announcement details a multi-phase CRI–10x collaboration to create AI-ready immuno-oncology datasets from over 20,000 samples and more than 500 million cells, leveraging Chromium, Xenium, and Chromium Flex. It extends prior AI partnerships and large-scale atlas efforts, emphasizing TXG’s platforms as a backbone for translational cancer research. Investors may watch for concrete outputs from the pilot phase, expansion to additional labs, and evidence that these datasets translate into new therapies or tools.

Key Terms

single cell, spatial data, immuno-oncology, microenvironmental

4 terms

single cell medical

"10x's Chromium single cell and Xenium spatial platforms with advanced AI"

Single cell refers to the study or use of an individual cell rather than averaging measurements across many cells. Like listening to a single voice in a crowded room, single-cell approaches reveal differences and rare cell types that bulk measurements hide. For investors, single-cell data can de-risk drug development and diagnostics by pinpointing precise targets, explaining why a therapy works or fails, and enabling more tailored products that may command premium pricing or faster regulatory paths.

spatial data medical

"generate single cell and spatial data from over 20,000 samples"

Spatial data is information tied to specific locations on Earth—such as coordinates, boundaries, or mapped areas—so you can see where assets, events or conditions are situated and how they relate across space. Investors use spatial data to assess real-world risks and opportunities—for example choosing property, planning logistics, targeting customers, or measuring environmental and regulatory exposure—much like using a map to pick the best route or site to minimize costs and maximize returns.

immuno-oncology medical

"advance the frontiers of immuno-oncology through high-resolution molecular data and AI"

Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.

microenvironmental medical

"determine which cellular and microenvironmental features are most predictive"

Microenvironmental describes the immediate physical and chemical surroundings of cells or tiny biological systems—for example, the mix of nearby cells, molecules, and conditions around a tumor or tissue. Like a neighborhood shaping how people behave, this local setting can change how a therapy works, how a disease progresses, or how a diagnostic performs. Investors care because treatments or products that successfully target or account for the microenvironment often show better results, face different development risks, and can command higher market value.

AI-generated analysis. Not financial advice.

Multi-phase initiative will generate single cell and spatial data from over 20,000 samples across leading immuno-oncology laboratories to map the immune landscape of cancer and drive the next generation of immunotherapies and vaccine discovery

PLEASANTON, Calif., Jan. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a collaboration with the Cancer Research Institute (CRI) to advance the frontiers of immuno-oncology through high-resolution molecular data and AI. The multi-phase project will combine 10x's Chromium single cell and Xenium spatial platforms with advanced AI to build one of the world's most comprehensive translational and preclinical immuno-oncology datasets, spanning more than 20,000 samples, to reveal how the immune system recognizes and responds to cancer and to inform smarter treatment and prevention strategies for the future. 

The initiative will begin with a pilot phase, supported by leading researchers at some of the world's top immuno-oncology laboratories, including John Wherry, Ph.D. (University of Pennsylvania), Ansuman Satpathy, M.D., Ph.D. (Stanford University) and Andrea Schietinger, Ph.D. (Memorial Sloan Kettering Cancer Center). Together, they intend to generate approximately 3,000 samples and analyze them using 10x's Chromium and Xenium platforms, which were selected for this project because they enable generation of large-scale, high-quality datasets with the resolution, consistency and throughput required for AI-driven immuno-oncology analyses. These pilot datasets will be used to benchmark early AI models and determine which cellular and microenvironmental features are most predictive in preclinical settings.

Following the pilot, the full project phase will expand to a broader network of laboratories, dramatically increasing the scale of sample generation across sites. To support this scale, CRI will incorporate 10x's Chromium Flex single cell assay, purpose-built for ultra high-throughput studies, to profile more than 500 million cells.  

CRI will use this integrated dataset to uncover mechanisms of immune response and resistance, refine and improve existing immuno-oncology treatments, identify opportunities for new therapeutic strategies and lay the groundwork for future vaccine discovery. Together, this work will deepen understanding of how to more effectively harness the immune system to prevent and treat cancer.

"At CRI, we've long focused on the three pillars of People, Biology, and Data. Now, with 10x Genomics, we're further delivering on our vision for Data by building the kind of high-resolution immune atlas that can redefine how cancer is prevented and treated. This collaboration brings 10x's extraordinary platforms together with CRI's singular mission and global research community to create insights that simply wouldn't exist otherwise," said Alicia Zhou, Ph.D, Chief Executive Officer of CRI.

"From the very beginning of 10x, we believed that deeply understanding biology at its most fundamental levels - cell by cell, in spatial context and at massive scale - would unlock breakthroughs that would transform human health," said Serge Saxonov, Chief Executive Officer and Co-founder of 10x Genomics. "Progress in immuno-oncology requires deciphering the mechanisms that shape therapeutic response. Partnering with CRI allows us to map these immune behaviors in unprecedented detail and build the scientific foundation for the next generation of immunotherapies and vaccines, bringing us closer to a future where cancer can become a thing of the past."

This initiative builds on CRI's long-standing approach of funding, connecting and accelerating immunotherapy discovery, from foundational biology to translational science and clinical application. It also further extends CRI's legacy of leadership in the field, including support for the studies that led to the HPV vaccine Gardasil®, one of the first cancer-preventive vaccines, and represents the next evolution of CRI's mission of a world immune to cancer by fueling the discovery and development of powerful immunotherapies for all cancers.

About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

About CRI

The Cancer Research Institute, established in 1953, is the preeminent U.S. nonprofit organization dedicated to saving more lives by fueling the discovery and development of powerful immunotherapies for all cancers. Guided by a world-renowned Scientific Advisory Council that includes five Nobel laureates and 35 members of the National Academy of Sciences, CRI has invested over $560 million in support of research conducted by immunologists and tumor immunologists at the world's leading medical centers and universities and has contributed to many of the key scientific advances that demonstrate the potential for immunotherapy to change the face of cancer treatment. Learn more at cancerresearch.org.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics' products and collaborations. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K, 10-Q and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. 10x Genomics' products are for research use only (RUO) and are not for use in diagnostic procedures. "10x Genomics", "Chromium" and "Xenium" are trademarks of 10x. 10x trademarks are the sole property of 10x, and are subject to legal protection in the United States and/or certain other countries.

Disclosure Information

10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cancer-research-institute-launches-transformative-ai-driven-immuno-oncology-initiative-powered-by-10x-genomics-technology-302657875.html

SOURCE 10x Genomics, Inc.

FAQ

What does the 10x Genomics and CRI collaboration announced Jan 12, 2026 (TXG) aim to achieve?

The collaboration aims to build an AI-ready immuno-oncology dataset from >20,000 samples and >500 million cells to map immune responses and inform immunotherapy and vaccine research.

How many samples will the pilot phase for TXG's CRI project include and which platforms will be used?

The pilot will generate approximately 3,000 samples and analyze them using 10x Chromium single cell and Xenium spatial platforms.

What is the planned cell throughput for the full phase of the TXG/CRI initiative?

The full project plans to profile more than 500 million cells using 10x's Chromium Flex single cell assay for ultra high-throughput studies.

How will early AI models be developed in the TXG and CRI initiative?

Pilot datasets from ~3,000 samples will be used to benchmark early AI models and identify cellular and microenvironmental features predictive in preclinical settings.

Which researchers and institutions are involved in the TXG/CRI pilot announced Jan 12, 2026?

Leading researchers include John Wherry (University of Pennsylvania), Ansuman Satpathy (Stanford University), and Andrea Schietinger (Memorial Sloan Kettering Cancer Center).